I've spent the past two years writing this report. I hope you enjoy it.

NeuroInsights Reveals Brain Industry's Investment Opportunities, Risks and Competitive Landscape in New Industry-Defining Report

SAN FRANCISCO--(BUSINESS WIRE)--May 11, 2005--NeuroInsights, the neurotechnology market authority, today announced the release of the industry's first comprehensive investment- and business-focused analysis of the neurotechnology marketplace. Titled "The Neurotechnology Industry 2005: Strategic Investment and Market Analysis Report of the Global Neurological Disease and Psychiatric Illness Markets," the 250 page report is the first publication to provide a unified market-based framework to help investors, companies and governments easily quantify opportunities, determine risks and understand the dynamics of this rapidly changing market.

The report's findings include:

-- NeuroInsights' Neurotech Index(TM) -- an investment benchmark that measures the stock performance of 30 publicly traded neurotechnology companies -- grew by 27.1 percent in 2004, compared to respective gains of 10.9 percent and 8.6 percent for the S&P 500 and NASDAQ Composite Index.

-- Neurological disease and psychiatric illness represent the largest and fastest growing unmet medical market: over 1.5 billion people worldwide and 100 million individuals in North America alone;

-- The neurotechnology industry has three sectors: neuropharmaceuticals with revenues of $87 billion and 13 percent growth annually; neurodevices with revenues of $2.8 billion and 20 percent growth annually; and neurodiagnostics with revenues of $12 billion and 11 percent growth annually;

-- VC investment in neurotechnology companies climbed 225 percent from 1999 to 2004 -- representing nearly $6 billion. Today, one-in-four VC dollars invested in Life Sciences goes to neurotechnology companies;

"It's an opportune time for investors to be looking at this market," said Zack Lynch, managing director of NeuroInsights. "The industry framework detailed in this report helps answer critical investment questions, such as: Who is investing in neurotechnology and what types of startups are getting funded? How are public neurotech companies performing compared to other industries? In what markets are neurodevices competing with neuropharmaceuticals?"

Pricing and Availability

The Neurotechnology Industry 2005: A Strategic Investment and Market Analysis Report of the Global Neurological Disease and Psychiatric Illness Markets." is available immediately. The 250 page report includes profiles of more than 300 public and private neurotechnology companies, products in clinical trials, and competitive analysis by market segment for more than 13 disorders, including Alzheimer's disease, attention deficit hyperactivity disorder, insomnia, depression, anxiety, epilepsy, addiction, stroke, schizophrenia, sensory disorders, Parkinson's disease and pain.

The cost of the report is $5,000 and can be ordered directly from NeuroInsightsor by calling 415-229-3225.